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Transforming growth factor-b (TGF-b) and interleukin-10 (IL-10) are regulatory cytokines with pleiotropic
roles in the immune system. The prominent function of TGF-b is to maintain T cell tolerance to self or innoc-
uous environmental antigens via its direct effects on the differentiation and homeostasis of effector and
regulatory T cells. A critical route for the regulation of T cells by TGF-b is via activation of a T cell-produced
latent form of TGF-b1 by dendritic cell-expressed avb8 integrin. IL-10 operates primarily as a feedback inhib-
itor of exuberant T cell responses to microbial antigens. T cells are also the principal producers of IL-10, the
expression of which is regulated by IL-27, IL-6, and TGF-b. The collective activity of TGF-b and IL-10 ensures
a controlled inflammatory response specifically targeting pathogens without evoking excessive immunopa-
thology to self-tissues.Introduction
As a consequence of incomplete presentation of self-antigens in
the thymus and the highly plastic nature of T cell receptor (TCR)
recognition of antigens, autoreactive T cells are present in
healthy individuals (Danke et al., 2004). Importantly, these auto-
reactive T cells are normally prevented from inducing autoim-
mune diseases. In addition, regulatory mechanisms are in place
to prevent collateral tissue damage as a result of exuberant T cell
responses to pathogens or innocuous environmental entities
such as the commensal flora. How self-inflicted inflammation is
controlled in the steady state and during infection is a topic of
active research. Previous studies with animal models have
established essential functions for the cytokines transforming
growth factor-b (TGF-b) and inerleukin-10 (IL-10) in inhibiting T
cell-mediated immunopathology (Li et al., 2006b; Moore et al.,
2001). In this review, we will discuss recent insights gained in
the understanding of the mechanisms by which TGF-b and
IL-10 regulate inflammatory T cell responses.
TGF-b Directly Targets Effector T Cells
and Treg Cells to Ensure Self-Tolerance
TGF-b belongs to a family of evolutionarily conserved molecules
with pleiotropic roles on multiple cell types that affect diverse
biological processes, including immune responses (Li et al.,
2006b). Three TGF-b members (TGF-b1, TGF-b2, and TGF-b3)
are present in mammals; TGF-b1 is the major form expressed
in the immune system.Active TGF-belicits its biological functions
through the TGF-b type I (TGF-bRI) and type II (TGF-bRII) recep-
tors. TGF-b engagement of the tetrameric receptor complex
activates the kinase activity of the receptors that subsequently
phosphorylate downstream targets and activate signaling path-
ways, which in some cases depend on the transcription-factor
Smad proteins (Derynck and Zhang, 2003; Shi and Massague,
2003).468 Immunity 28, April 2008 ª2008 Elsevier Inc.The pivotal functions of TGF-b in immune tolerance were orig-
inally revealed in the studies of TGF-b1-deficient mice that
develop an early and fatal multi-focal inflammatory disease
(Kulkarni et al., 1993; Shull et al., 1992). T cells are essential me-
diators of the disease because depletion of CD4+ or CD8+ T cells
alleviates the immunopathology (Kobayashi et al., 1999; Letterio
et al., 1996). The failure to rescue the inflammatory phenotype
under germ-free conditions suggests that the T cell-driven in-
flammation is of autoimmune origin (Boivin et al., 1997). Because
TGF-b1 modulates the activities of multiple lineages of leuko-
cytes, it was not clear from these early reports whether TGF-b1
directly controls T cell tolerance. Studies with transgenic mice
expressing dominant-negative mutants of TGF-bRII in T cells,
and more recently with T cell-specific TGF-bRII-deficient mice,
have firmly established T cells as a principal direct TGF-b1 target
in vivo (Gorelik and Flavell, 2000; Li et al., 2006a; Lucas et al.,
2000;Marieetal., 2006). In the absence of TGF-b signaling, T cells
undergo hyperproliferation, activation, and effector T cell differ-
entiation that result in infiltration of leukocytes into multiple vital
organs and a neonatal lethal phenotype as severe as that of TGF-
b1-deficient mice (Li et al., 2006a; Marie et al., 2006). These
observations demonstrate that TGF-b signaling in T cells is indis-
pensable for restraining relentless self-directed T cell responses
in peripheral tissues.
Another essential pathway of peripheral T cell tolerance is
mediated by CD4+ regulatory T (Treg) cells that express the tran-
scription factor Foxp3 (Sakaguchi, 2004; Zheng and Rudensky,
2007). In the absence of TGF-b signaling in T cells, thymic Treg
cell numbers are not reduced (Li et al., 2006a; Marie et al.,
2006). However, Treg cells progressively diminish in the periph-
eral lymphoid organs, notably in the spleens of these mice (Li
et al., 2006a; Marie et al., 2006). These findings are in line with
an early report using TGFb1-deficient mice (Marie et al., 2005).
Foxp3 controls the genetic program critical for the suppressive
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cell-dependent inflammatory phenotype similar in severity to
that of T cell-specific TGF-bRII-deficient mice (Brunkow et al.,
2001; Fontenot et al., 2003). Therefore, it was an open question
whether the loss of T cell tolerance in TGF-bRII-deficient mice
was caused by reduced Treg cells or was due to the lack of
cell-intrinsic control of effector T cell activation by TGF-b. On
the other hand, failed maintenance of TGF-bRII-deficient Treg
cells might be caused by environmental changes such as the
inflammatory disorder developed in these mice, or it might be
a direct consequence of a lack of TGF-b signaling in Treg cells.
These questions were addressed in a series of transfer and
bone-marrow chimera experiments. Transfer of wild-type Treg
cells to neonatal TGF-bRII-deficient mice restored Treg cell num-
bers to those found in wild-typemice but was unable to correct T
cell activation and autoimmune diseases (Li et al., 2006a). Thus,
the depletion of Treg cells does not solely account for the loss of
T cell tolerance in these mice. These findings are consistent with
earlier reports showing that effector T cells expressing a domi-
nant-negative mutant of TGF-bRII cannot be suppressed by
Treg cells in colitis, diabetes, or tumor models (Chen et al.,
2005; Fahlen et al., 2005; Green et al., 2003; Mempel et al.,
2006). The functions of TGF-b signaling in the control of effector
T cells and Treg cells have been further investigated in mixed
bone-marrow chimera experiments. By creating chimeric mice
that harbor both wild-type and TGF-bRII-deficient T cells, T
cell-intrinsic effects can be differentiated from T cell-extrinsic
environmental causes. Interestingly, the T cell compartments
of TGF-bRII-deficient mice exhibit a more activated phenotype
and contain lower Treg cell numbers than the wild-type T cell
populations in the same chimera (Li et al., 2006a; Marie et al.,
2006). These findings have therefore established cell-intrinsic
roles for TGF-b signaling in the control of both effector T cells
and Treg cells (Figure 1A), which might collectively contribute
to the maintenance of T cell tolerance.
TGF-b Regulation of Induced Treg Cell
and Th17 Cell Differentiation
In addition to the thymus-produced naturally occurring Treg
(nTreg) cells, naive T cells can acquire Foxp3 expression and dif-
ferentiate into the induced Treg (iTreg) cells in peripheral tissues.
TGF-b induces Foxp3 expression and iTreg cell differentiation
from CD4+CD25 or CD4+Foxp3 T cells in vitro (Chen et al.,
2003; Fantini et al., 2004; Wan and Flavell, 2005; Zheng et al.,
2002). Optimal induction of Foxp3 expression and expansion of
TGF-b-induced iTreg cells is dependent on T cell-produced cyto-
kine IL-2 (Davidson et al., 2007; Zheng et al., 2007), which also
promotes the differentiation of thymic nTreg cells. Interestingly,
overexpression of TGF-b1 in the islets of the pancreas expands
Treg cells that protect NOD mice from diabetes (Peng et al.,
2004). These observations suggest that when TGF-b is present
in excess, it induces the generation and/or maintenance of Treg
cells. EndogenousTGF-bmight alsobe involved in thegeneration
of iTreg cells in periphery tissues. Delivery of low-dose agonistic
peptide to dendritic cells induces iTreg cell differentiation from
antigen-specific naive T cells (Kretschmer et al., 2005). The effi-
ciency of iTreg cell induction is inversely correlated with cell
proliferation and is inhibited when T cells are stimulated in the
presence of costimulatory signals or with high-dose antigens.Although hyperproliferation is inhibitory for the induction of iTreg
cells, converted iTreg cells maintain a stable phenotype and can
be expanded upon immunization with antigens in the presence
of adjuvant in this model (Kretschmer et al., 2005). Inhibition of
TGF-b signaling in T cells via the expression of a dominant-
negative mutant of TGF-bRII suppresses iTreg cell generation,
which is associated with the enhanced T cell proliferation
(Kretschmer et al., 2005). It is an open question whether TGF-b
inhibition of T cell proliferation provides the mechanism for its
promotion of iTreg cell differentiation in this model. To what
extent iTreg cells produced via this pathway contribute to the
peripheral Treg cell pool also remains to be determined.
Recent studies have revealed that the gut-associated lym-
phoid tissue (GALT) might be a particularly important site for
the generation of iTreg cells. Transfer of polyclonal CD4+Foxp3
T cells to the congenic recipient mice results in the conversion of
a subset of these T cells to iTreg cells that accumulate in the
GALT (Sun et al., 2007). Administration of oral antigens also in-
duces iTreg cell differentiation from naive CD4+Foxp3 trans-
genic T cells (Coombes et al., 2007). The preferential induction
of iTreg cells at the mucosal site has been attributed to the
GALT CD103+ dendritic cells that produce high amounts of the
vitamin A metabolite retinoid acid (RA). The addition of neutraliz-
ing TGF-b antibody or RA receptor inhibitors attenuate the gen-
eration of iTreg cells, whereas the presence of RA in T cell culture
potentiates TGF-b-induced iTreg cell differentiation (Benson
et al., 2007; Coombes et al., 2007; Mucida et al., 2007; Sun
et al., 2007). RA produced by GALT dendritic cells is also essen-
tial for the induction of the gut-homing receptors on T cells (Iwata
et al., 2004). These studies have thus revealed a TGF-b and
RA-dependent pathway for the generation and homing of iTreg
cells to the GALT (Figure 1A); such a pathway might provide an
important mechanism for T cell tolerance to antigens derived
from commensal flora or of dietary origin.
TGF-b induction of iTreg cell differentiation is inhibited in the
presence of the pro-inflammatory cytokine IL-6 (Bettelli et al.,
2006). Instead, TGF-b plus IL-6 leads to the generation of the
newly characterized T helper cells, Th17 cells, from naive T cells
(Bettelli et al., 2006; Veldhoen et al., 2006a) (reviewed by
McGeachy and Cua (2008) in this issue of Immunity). Th17 cells
produce a distinct subset of cytokines, including IL-17A, IL-17F,
and IL-22, that act on a broad range of innate immune and non-
hematopoietic cells to regulate host defense and tissue homeo-
stasis (Weaver et al., 2006) [(reviewed in this issue by Ouyang
et al. (2008)]. In addition, Th17 cells are the culprits of the adju-
vant-induced autoimmune diseases, including experimental al-
lergic encephalomyelitis (EAE) (Cua et al., 2003; Langrish et al.,
2005). Although TGF-b and IL-6 are essential inmice for the initial
commitment of CD4+ T cells to the Th17 cell lineage, they are not
sufficient to induce pathological Th17 cells. Using a transfer
model of EAE, a recent study showed that Th17 cells that are ex-
panded in the presence of the pro-inflammatory cytokine IL-23,
but not with TGF-b plus IL-6, induce disease in mice (McGeachy
et al., 2007). Th17 cells stimulated with TGF-b plus IL-6 produce
high amounts of the anti-inflammatory cytokine IL-10 (discussed
below) but low amounts of inflammatory chemokines and IL-22.
Interestingly, IL-10 produced by Th17 cells that have been ex-
panded with TGF-b plus IL-6 suppresses the immunopathology
induced by IL-23-stimulated Th17 cells. These observationsImmunity 28, April 2008 ª2008 Elsevier Inc. 469
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(A) TGF-b controls T cell tolerance via its direct inhibition of T
helper 1 (Th1), Th2, and cytotoxic T lymphocyte (CTL) differen-
tiation and the maintenance of regulatory T (Treg) cells. TGF-
b promotes the differentiation of induced Treg (iTreg) cells;
this differentiation is enhanced by IL-2 and retinoid acid
(RA). In the presence of IL-6, TGF-b drives the differentiation
of Th17 cells and maintains these cells at a regulatory state
(rTh17). IL-23 stimulation of rTh17 cells in the absence of
TGF-b induces their differentiation into effector Th17 cells
(eTh17) with essential functions in immunity.
(B) A ‘‘three-cell’’ model for TGF-b1-dependent regulation of T
cell responses. Upon stimulation by dendritic cells (DCs), Treg
cells secrete the latent form of TGF-b1 (*TGF-b1) made of
a TGF-b1 dimer associated with the latency-associated pro-
tein (LAP). DC-expressed avb8 integrin interacts with LAP
and induces the degradation of LAP and the release of active
TGF-b1. Active TGF-b1 subsequently acts on naive CD4+ T
cells via a paracrine mechanism to inhibit their differentiation
to Th1 or Th2 cells and to promote their differentiation to iTreg,
rTh17, or eTh17 cells. Activated CD4+ T cells produce some
amounts of *TGF-b1 that can regulate T cell differentiation
through an autocrine route.suggest that TGF-b plus IL-6 drives the differentiation of Th17
cells to a state with regulatory activities (regulatory Th17,
rTh17) and that stimulation and expansion of rTh17 cells by
IL-23 in the absence of TGF-b leads to the acquisition of effector
Th17 cell activities (effector Th17, eTh17) (Figure 1A). To this end,
it is interesting to note that TGF-b inhibits IL-23R expression
induced by IL-6 in Th17 cells (Zhou et al., 2007). Therefore, it is
conceivable that continued stimulation of Th17 cells by TGF-b
might limit their responses to IL-23 and maintain Th17 cells in
the nonpathological regulatory state.
The involvement of TGF-b in the differentiation of both Th17
cells and iTreg cells suggests a special kinship between these
two lineages of CD4+ T cells. However, the induction of Th17
cells and that of iTreg cells appear to be mutually exclusive.
Under the settings that favor Th17 cell differentiation, i.e., TGF-b
plus IL-6, iTreg cell generation is inhibited (Bettelli et al., 2006),
whereas under the conditions that promote iTreg cell produc-
tion, i.e., TGF-b plus IL-2 and RA, Th17 cell differentiation is blo-
cked (Laurence et al., 2007; Mucida et al., 2007). The molecular
mechanisms underlying the reciprocal differentiation of Th17
and iTreg cells remain to be determined. Th17 cells, presumably
in the regulatory state, are present constitutively at high frequen-
cies in the mouse intestinal lamina propria (Ivanov et al., 2006).
The GALT is also probably an important site for the generation
of iTreg cells. These observations suggest that TGF-b-induced
Th17 cells and iTreg cells have important functions in the regula-
tion of mucosal immune responses. To this end, it is interesting
to note that TGF-b also promotes B cell class switching to IgA
isotypes that are critically involved in the mucosal immune
defense (Li et al., 2006b). Therefore, the positive effects of
TGF-b on T and B lymphocyte differentiation might have been
selected during evolution to fulfill the special needs of mucosal
immune homeostasis.
Control of T Cell Responses by T Cell-Produced TGF-b1
TGF-b1 is a widely distributed cytokine that is produced by
almost all cell types (Li et al., 2006b). In an early report, liver-spe-470 Immunity 28, April 2008 ª2008 Elsevier Inc.cific expression of an active form of TGF-b1 restores the circulat-
ing TGF-b1 levels in TGF-b1-deficient mice but fails to rescue the
lethal phenotype (Longenecker et al., 2002), suggesting that
paracrine and/or autocrine sources of TGF-b1 are essential
for the control of T cell tolerance. To address the function of
T cell-produced TGF-b1, a recent study used a mouse strain in
which the Tgfb1 gene was inactivated in T cells (Li et al., 2007).
In the absence of T cell-produced TGF-b1, mice developwasting
colitis associated with T cell hyperproliferation, activation, and
effector T cell differentiation, suggesting that T cell-produced
TGF-b1 directly regulates T cells. Previous studies showed that
TGF-b signaling in T cells is essential for the maintenance of pe-
ripheral Treg cells (Li et al., 2006a; Marie et al., 2006). However,
despite decreased numbers of peripheral Treg cells, TGF-bRII-
deficient Treg cells undergo enhanced cell proliferation (Li
et al., 2006a). Therefore, the TGF-b pathway has a dual function
in the suppression of Treg cell proliferation and the maintenance
of Treg cells. In the absence of T cell-produced TGF-b1, Treg
cells expand in the lymph nodes and spleens, revealing that T
cell-produced TGF-b1 is essential for the inhibition of Treg cell
proliferation but is dispensable for Treg cell maintenance in these
tissues. Interestingly, colonic Treg cells from these mice express
lower amounts of Foxp3 than Treg cells from the peripheral
lymph nodes (Li et al., 2007). It is possible that the diminished
expression of Foxp3 in colonic Treg cells is a consequence of
colitis developed in these mice. Alternatively, because TGF-b
is involved in the differentiation of iTreg cells in the GALT (dis-
cussed in the previous section), T cell-produced TGF-b1 might
be required for the de novo generation ormaintenance of colonic
iTreg cells. These findings suggest that T cell-produced TGF-b1
regulates mucosal T cell tolerance via its inhibition of effector
T cell differentiation, and possibly also through the promotion
of colonic iTreg cell differentiation (Figure 1B).
Both Treg cells and naive CD4+ T cells produce TGF-b1 upon
TCR stimulation in vitro (Li et al., 2007). To further delineate the
functions of TGF-b1 produced by the subsets of T cells in vivo,
Li et al. used an adoptive-transfer model of colitis. In this model,
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colitis, which can be prevented by the cotransfer of Treg cells.
Early studies showed that Treg cell-mediated protection is abro-
gated by the treatment of TGF-b neutralization antibody (Powrie
et al., 1996) and that naive CD4+ T cells expressing a dominant-
negative mutant of TGF-bRII are refractory to Treg cell-induced
suppression (Fahlen et al., 2005). Therefore, Treg cell inhibition
of colitis is dependent on TGF-b signaling in T cells. However,
whether the Treg cell is the source cell type for TGF-b1 is contro-
versial (Fahlen et al., 2005; Kullberg et al., 2005; Nakamura et al.,
2004). In a series of transfer experiments, CD4+Foxp3+ Treg cells
isolated from T cell-specific TGF-b1-deficient mice were shown
to be incapable of suppressing colitis induced by wild-type naive
T cells; this was associated with the failed inhibition of naive
T cell differentiation into Th1 cells (Li et al., 2007). The transfer
experiments have also shown that, to a lesser extent, TGF-b1
originated from naive T cells could contribute to the protection
of colitis. Treg cells express membrane-bound TGF-b1 (Green
et al., 2003; Nakamura et al., 2001; Oida et al., 2003), which
has been implicated in Treg cell suppression. However, the de-
finitive contribution of surface and/or soluble TGF-b1 produced
by Treg cells remains to be determined. In addition, TGF-b1-
deficient Treg cells have normal suppressive activity in vitro (Li
et al., 2007). Foxp3-deficient mice also develop a more severe
phenotype than T cell-specific TGF-b1-deficient mice. There-
fore, production of TGF-b1 is likely to be one of many mecha-
nisms that Treg cells utilize to regulate T cell tolerance.
In the EAEmodel, neutralization of TGF-b1 at the site of immu-
nization inhibits Th17 cell differentiation and disease develop-
ment (Veldhoen et al., 2006b), suggesting that TGF-b1 regulation
of Th17 cell differentiation also occurs via the paracrine and/or
autocrine route. T cell production of IL-17 is greatly reduced in
T cell-specific TGF-b1-deficient mice (Li et al., 2007). In addition,
these mice are highly resistant to EAE, which is associated with
the failed differentiation of Th17 cells (Li et al., 2007). These find-
ings demonstrate that T cell-produced TGF-b1 is indispensable
for Th17 cell differentiation in vivo (Figure 1B). However, it re-
mains to be determined whether TGF-b1 produced by Treg cells,
non-Treg T cells, or both is involved in Th17 cell differentiation. It
has been shown that Treg cells potentiate Th17 cell differentia-
tion induced by dendritic cells in vitro (Veldhoen et al., 2006a;
Xu et al., 2007). In a transfer model of systemic autoimmune
disease, cotransfer of Treg cells inhibits IFN-g but enhances
IL-17 production from effector T cells (Lohr et al., 2006). These
observations suggest a pro-inflammatory function for Treg cells
in promoting Th17 cell differentiation through the production of
TGF-b1. Future studies with Treg cell-specific TGF-b1-deficient
mice will help to test this hypothesis.
TGF-b1 Activation by Dendritic
Cell-Produced avb8 Integrin
TGF-b1 is synthesized and produced as a latent form that needs
activation to be functional (Li et al., 2006b). A homodimer of the
TGF-b1 propeptide, the latency-associated protein (LAP), is
constitutively associated with the mature TGF-b1, which pre-
vents TGF-b1 from binding to its receptors. TGF-b1 activation
proceeds via the degradation of LAP or the alteration of LAP con-
formation; this can be mediated by proteases, including plasmin
andmatrixmetalloproteinases, thrombospondin-1, and integrinsavb6 or avb8 (Annes et al., 2003). Activation of TGF-b1 by avb6
or avb8 integrin is dependent on their binding to an RGD motif in
LAP but proceeds through different mechanisms. avb6 integrin
induces mechanical traction of LAP and activates TGF-b1 in
the absence of its release from the latent complexes (Munger
et al., 1999). On the other hand, avb8 integrin-induced TGF-b1
activation requires metalloproteinase-mediated degradation of
LAP, which results in the release of active TGF-b1 into the extra-
cellular space (Mu et al., 2002). In a recent report, the in vivo
function of the integrin-dependent TGF-b1 activation was stud-
ied in a mouse model in which the TGF-b1 RGD sequence was
substituted with the RGE sequence (Yang et al., 2007). The
D-to-E amino acid change abolishes the integrin-dependent
activation of TGF-b1 but preserves TGF-b1 processing and
secretion. Interestingly, mice homozygous for the Tgfb1 D-to-E
allele develop an autoimmune phenotype that is indistinguish-
able from that of TGF-b1-deficient mice. These observations
demonstrate a pivotal function for the integrin pathway in the
activation of TGF-b1 in vivo.
avb6 integrin is expressed in epithelial cells. avb6-deficient
mice are viable and do not suffer from T cell-mediated inflamma-
tion. avb8 integrin is expressed in multiple cell types, including T
cells and dendritic cells. avb8 integrin deficiency in mice is em-
bryonic lethal. To investigate the function of avb8 integrin in adult
mice, researchers have used mouse strains that harbor floxed
alleles of Itgb8 or Itgav genes. Ablation of b8 in dendritic cells, but
not in T cells, results in colitis inmice; this is associatedwith T cell
activation and differentiation, as well as reduced colonic Treg
cells (Travis et al., 2007). In addition, b8-deficient dendritic cells
fail to activate TGF-b1 and are unable to induce iTreg cell differ-
entiation in vitro. Similar colitis and T cell phenotypes are present
in mice in which the Itgav gene is deleted from myeloid cells
(Lacy-Hulbert et al., 2007). Intriguingly, inflammation and T cell
activation in the dendritic cell-specific avb8 integrin-deficient
mice are remarkably similar to what is observed in mice with T
cell-specific deletion of the Tgfb1 gene (Li et al., 2007). These
findings prompt us to propose a ‘‘three-cell’’ model for TGF-
b1-dependent regulation of T cell responses (Figure 1B). In this
model, Treg cells, and to a lesser extent naive T cells, produce
latent TGF-b1 upon TCR stimulation by dendritic cells. Latent
TGF-b1 is activated through mechanisms that are dependent
on avb8 integrin expressed by dendritic cells, which creates an
active TGF-b1 milieu around the dendritic cells. Active TGF-b1
subsequently acts on naive T cells to regulate their activation
and differentiation induced by dendritic cells. The involvement
of dendritic cells in Treg cell-mediated immune regulation as
proposed in this model is consistent with a previous study that
showed that Treg cells form long-lasting interactions with
dendritic cells in vivo; these interactions subsequently impair
the ability of dendritic cells to drive the differentiation of effector
T cells (Tang et al., 2006). However, it is important to note that the
inflammatory phenotypes developed in T cell-specific TGF-b1-
deficient mice are less severe than those of mice with TGF-b1
deficiency in all cells. In addition, dendritic cell-specific b8 integ-
rin-deficient mice suffer frommilder inflammation than mice with
D-to-E alleles of integrin-activation-defective TGF-b1 mutants.
These observations suggest that TGF-b1 produced by cell types
other than T cells, and integrins other than dendritic cell-
expressed avb8, is also important in the regulation of T cells.Immunity 28, April 2008 ª2008 Elsevier Inc. 471
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help us better understand the cellular mechanisms by which
TGF-b1 regulates T cells.
IL-10 as a Gatekeeper of Exuberant Immune Reponses
to Foreign Antigens
IL-10 is a regulatory cytokine with pleiotropic effects on multiple
cell types that express IL-10 receptor 1 (IL-10R1) and IL-10 re-
ceptor 2 (IL-10R2) (Moore et al., 2001). IL-10 engagement of its
receptor complex initiates diverse signaling, including the activa-
tion of the Jak1 and Tyk2 kinases and the Stat3 transcription fac-
tor [reviewed in this issue by O’Shea andMurray (2008)], in target
cells. An essential function for IL-10 in immune tolerance was
first revealed in the study of IL-10-deficient mice that develop
lethal colitis in specific-pathogen-free facilities (Kuhn et al.,
1993). Colitis in these mice is mediated by T cells that undergo
activation and effector T cell differentiation in the absence of
IL-10. T cell activation or colitis is inhibited when IL-10-deficient
mice are raised under the germ-free conditions (Kuhn et al.,
1993; Sellon et al., 1998), demonstrating that IL-10 functions to
maintain T cell tolerance to resident enteric bacteria antigens.
Similar to pathological microbes, commensal bacteria display
the conserved molecular patterns that can be recognized by
the innate immune system’s pattern-recognition receptors,
such as the Toll-like receptors (TLRs). Interestingly, deficiency
of the TLR signaling molecule MyD88 blocks the development
of colitis in IL-10-deficient mice (Rakoff-Nahoum et al., 2006).
These findings suggest that in the steady state, IL-10 inhibits T
cell responses induced by TLR-stimulated innate immune cells
in recognition of commensal bacteria antigens (Figure 2A).
The adaptive immune system has evolved to combat patho-
gens efficiently, which is orchestrated by the elaborated effector
T cells tailed to the specific pathogens. However, exuberant T
cell responses can result in the development of immunopathol-
ogy and sometimes induce more severe tissue damage than
infection itself. Therefore, regulatory mechanisms are in force
to control the magnitude of effector T cell responses. The use
of various infection models has helped to demonstrate that
IL-10 functions to limit the extent of immune responses to foreign
pathogens (Moore et al., 2001). This can lead to the dual conse-
quences of either the inhibition of collateral tissue damage, such
as that which occurs during Toxoplasma gondii or Trypanosoma
cruzi infection (Gazzinelli et al., 1996; Hunter et al., 1997), or the
promotion of a chronic infection state in the case of Leishmania
major or lymphocytic choriomengitis virus infection (Belkaid
et al., 2002; Brooks et al., 2006; Ejrnaes et al., 2006; Kane and
Mosser, 2001). The importance of IL-10 in controlling infection
is underscored by the finding that some pathogens, such as
the Epstern-Barr virus, encode IL-10 homologs in their genome
(Moore et al., 1990). The viral IL-10 molecules have regulatory
activity similar to that of the host IL-10 and might therefore
play an important role in host-pathogen interactions. Taken to-
gether, these findings suggest that the IL-10 pathway is a critical
regulator of immune responses to microorganisms, including
both the innocuous commensal flora and the pathogens.
How IL-10 regulates T cell responses is incompletely under-
stood. IL-10 potently inhibits the functions of antigen-presenting
cells such as dendritic cells and macrophages through the re-
pression of inflammatory cytokine production and the inhibition472 Immunity 28, April 2008 ª2008 Elsevier Inc.of MHC class II and costimulatory-molecule expression (Moore
et al., 2001). A potential role for IL-10 signaling in macrophages
is supported by the study ofmacrophage and neutrophil-specific
Stat3-deficient mice that develop chronic colitis (Takeda et al.,
1999). However, because Stat3 is activated by multiple cytokine
signaling pathways, the relevance of IL-10 in this model of colitis
awaits further investigation. IL-10 might also directly regulate
T cells. IL-10 enhances the differentiation of antigen-driven
IL-10-producing CD4+ regulatory T (Tr1) cells in vitro (Groux
et al., 1997). A recent study showed that during Listeria monocy-
togenes infection, deficiency of IL-10R2 in antigen-specific CD8+
T cells, but not in antigen-presenting cells, leads to the increased
expansion of CD8+ T cells (Biswas et al., 2007). Therefore, the
IL-10 direct target cells involved in IL-10-mediated regulation
of T cell responses remain to be fully characterized andwill prob-
ably be resolved with the generation of cell-type-specific IL-10
receptor-deficient mice.
Control of T Cell Responses by T Cell-Produced IL-10
IL-10 was originally identified as a molecule that is produced by
Th2 cells and inhibits Th1 cell responses (Fiorentino et al., 1989).
Figure 2. IL-10 Regulation of T Cells
(A) IL-10 controls T cell tolerance at the interface between the innate and the
adaptive immune systems. Microbial stimulation of antigen-presenting cells
(APCs) via the pattern-recognition receptors (PRRs) such as the Toll-like
receptor (TLR) induces APC maturation; this is associated with the induction
of major histocompatibility complex (MHC) and costimulatory molecule
(CSM) gene expression, and the secretion of innate immune cytokines. IL-10
may directly inhibit the APC maturation process. In addition, IL-10 may act
on T cells to inhibit effector T cell differentiation stimulated by the mature
APCs.
(B) Upon stimulation by APCs, IL-10 can be produced by multiple T cell types,
including Treg, rTh17, Th1, Th2, and CTL cells. IL-10 production in T cells is
regulated by the innate immune cytokines IL-27 and IL-6 with the aid of
TGF-b.
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CD8+ T cells, as well as by CD4+Foxp3+ Treg cells and CD4+ Tr1
cells. In addition, antigen-presenting cells also produce IL-10 in
response to pathogen infection. The functions of IL-10 produced
by specific cell types have been studied with a strain of condi-
tionally IL-10-deficient mice. Similar to completely IL-10-defi-
cient mice, mice with a T cell-specific inactivation of the Il10
gene develop colitis and succumb to severe immunopathology
upon infection with T. gondii; this is associated with enhanced
T cell activation and differentiation (Roers et al., 2004). However,
abrogation of IL-10 expression in T cells does not affect innate
immune responses to lipopolysaccharide, which is controlled
by IL-10 produced by macrophages and neutrophils (Siewe
et al., 2006). These findings suggest that IL-10 is involved in
the feedback control of immune responses and that the func-
tions of effector cells are inhibited by IL-10 produced by the
same cell type.
Consistent with the notion that IL-10 can function as a feed-
back regulator of T cells, recent studies have shown that Th1
cell-produced IL-10 is essential for the inhibition of exaggerated
Th1 cell responses during infection. CD4+ T cells producing high
amounts of IFN-g are also the source cells of the IL-10 that
inhibits the development of immunopathology upon T. gondii in-
fection (Jankovic et al., 2007). These T cells express the Th1 cell
lineage transcription factor T-bet, but not the Treg cell marker
Foxp3. Therefore, they are by all criteria the classic T. gondii
antigen-specific Th1 cells. In another infection model using an
L. major strain (NIH/Sd) that induces nonhealing lesions in in-
fected mice, IL-10 produced by Th1 cells is also found to be re-
sponsible for the hindrance of immune responses to L. major and
as a consequence to promote lesion development (Anderson
et al., 2007). Whether similar feedback regulation also operates
in Th2, Th17, and CD8+ T cells remains to be determined. It is
nevertheless tempting to speculate that IL-10 might have
evolved to function as a general inhibitor involved in the auto-
regulation of effector T cell responses.
In addition to effector T cells, Treg cells produce IL-10. In an
adoptive-transfer model of colitis, CD4+CD45RBlow T cell inhibi-
tion of CD4+CD45RBhigh naive T cell-induced colitis in lympho-
penic hosts is reversed by administration of an anti-IL-10 recep-
tor antibody (Asseman et al., 1999). CD4+CD45RBlow T cells from
IL-10-deficient mice also fail to protect mice from colitis. These
findings are in line with the aforementioned study of T cell-spe-
cific IL-10-deficient mice that develop spontaneous colitis. The
CD4+CD45RBlow T cell population is enriched for CD4+Foxp3+
Treg cells. Therefore, it is possible that IL-10 produced by Treg
cells is involved in the inhibition of colitis in mice. This conclusion
is supported by the observation that mice with the Treg cell-spe-
cific deletion of the Il10 gene develop colitis (Rubtsov et al., 2008,
in this issue). In a model of infection with the Friedlin strain of
L. major, production of IL-10 by Treg cells has also been associ-
ated with the failed eradication of the pathogens (Belkaid et al.,
2002). Nevertheless, because IL-10 is produced by both Treg
cells and effector T cells, the definitive functions of Treg cell-
produced IL-10 in this model remain to be established.
Regulation of IL-10 Production in T Cells
The promiscuous expression pattern of IL-10 in T cells prompts
the studies on the mechanisms involved in the regulation ofIL-10 expression in these cells. To mark IL-10 producers
in vivo, several groups have developed IL-10 reporter mouse
strains (Calado et al., 2006; Kamanaka et al., 2006; Maynard
et al., 2007). IL-10-producing T cells are absent in the thymus
but can be detected at varying frequencies in peripheral tissues
and are highly abundant in mouse intestines (Kamanaka et al.,
2006; Maynard et al., 2007). TCR stimulation of T cells in vivo in-
duces IL-10 expression; the major producers are the Peyer’s
patch T cells and the intraepithelial lymphocytes in the large
and small intestines (Kamanaka et al., 2006). The prominent dis-
tribution of IL-10-producing T cells in the intestine is consistent
with the critical function of T cell-produced IL-10 in the mainte-
nance of immune tolerance to commensal bacteria antigens in
mice. Using dual-reporter mouse strains for IL-10 and Foxp3
has revealed IL-10-producing cells among the Foxp3+ Treg cells
in the large intestine and among the Foxp3 T cells in the small
intestine (Kamanaka et al., 2006). So that the lineage relationship
of these IL-10-producing T cells could be determined, a series of
transfer experiments were performed. Thymic CD4+Foxp3+ Treg
cells give rise to the peripheral Foxp3+IL-10+ and Foxp3+IL-10
Treg cells, whereas thymic CD4+Foxp3 T cells differentiate
into Foxp3+IL-10+ or Foxp3+IL-10 Treg cells, as well as the
Foxp3-IL-10+ T cells (Maynard et al., 2007). Interestingly, all three
T cell subsets are present in IL-10-deficient mice but are reduced
in mice treated with neutralizing TGF-b antibody (Maynard et al.,
2007). These findings have therefore revealed an interrelation
between TGF-b and IL-10 in immune tolerance and are also
consistent with the known function of TGF-b in iTreg cell differen-
tiation.
TGF-b promotes TCR-stimulated naive T cells to differentiate
into iTreg cells but is not sufficient to trigger high IL-10 produc-
tion in T cells. Recent studies have shown that cytokines IL-27
and IL-6 are important regulators of IL-10-producing T cells
(Awasthi et al., 2007; Fitzgerald et al., 2007; McGeachy et al.,
2007; Stumhofer et al., 2007) (Figure 2B). IL-27 is a heterodimeric
cytokine produced mostly by innate immune cells (Kastelein
et al., 2007). Although IL-27 was initially identified as a molecule
that promotes Th1 cell differentiation, recent studies have shown
that IL-27 limits Th1, Th2, and Th17 cell responses in various in-
fection and autoimmune disease models (Kastelein et al., 2007).
The presence of IL-27 in T cell culture inhibits the production of T
cell effector cytokines but markedly enhances IL-10 production
by both CD4+ and CD8+ T cells (Awasthi et al., 2007; Fitzgerald
et al., 2007; Stumhofer et al., 2007). Interestingly, TGF-b further
augments IL-27-induced IL-10 expression in CD4+ T cells (Awas-
thi et al., 2007; Stumhofer et al., 2007), which reveals another
connection between TGF-b and IL-10. IL-27 promotion of IL-10
production in CD4+ T cells is observed under neutral, Th1, or
Th2 polarizing conditions. The importance of IL-27 in the differ-
entiation of IL-10-producing T cells in vivo has been further cor-
roborated by the observation that IL-10+IFN-g+ Th1 cells are
absent in IL-27 receptor-deficient mice infected with T. gondii
(Stumhofer et al., 2007). In T. gondii-infected mice, IL-10 pro-
duced by Th1 cells is essential for the inhibition of an excessive
Th1 cell response that induces immunopathology in mice
(Jankovic et al., 2007). Consistent with an indispensable role
for IL-27 in IL-10 production, IL-27 receptor-deficient mice
develop lethal CD4+ T cell-mediated inflammation upon T. gondii
infection (Villarino et al., 2003). IL-6 plus TGF-b-induced Th17Immunity 28, April 2008 ª2008 Elsevier Inc. 473
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Reviewcells produce high amounts of IL-10 whose expression is not
further enhanced by IL-27 (Stumhofer et al., 2007). However,
similar to IL-27-induced IL-10 expression, Th17 cell production
of IL-10 is dependent on the synergistic activity of both IL-6
and TGF-b (Stumhofer et al., 2007). Both IL-6 and IL-27 are
type I cytokines with a shared receptor subunit and activate
Stat transcription factors in target cells [reviewed in this issue
by O’Shea and Murray (2008)]. Interestingly, IL-27 induction of
IL-10 expression is dependent on both Stat1 and Stat3, whereas
only Stat3 is required for IL-6 promotion of IL-10 production
(Stumhofer et al., 2007). In addition, TGF-b-induced IL-10 pro-
duction in T cells is associated with the binding of the Smad4
transcription factor to the Il10 gene promoter (Kitani et al.,
2003). Nevertheless, the precise epigenetic mechanisms by
which Stat, Smad, and other transcription factors regulate
IL-10 expression in T cells remain to be determined.
Conclusions
TGF-b1 and IL-10 are regulatory cytokines with pivotal functions
in the control of inflammation. TGF-b1 directly targets T cells to
ensure immune tolerance to self- and environmental antigens,
whereas IL-10 regulates at the interface of innate and adaptive
immunity to limit the magnitude of immune responses to micro-
bial antigens. T cells are the essential producers of both TGF-b1
and IL-10 involved in the regulation of T cell responses. Mobiliza-
tion of T cell-produced TGF-b1 requires the engagement of
dendritic cell-expressed avb8 integrin that activates the latent
form of TGF-b1, whereas T cell production of IL-10 is regulated
by innate immune cytokines IL-27 and IL-6. In addition, the
TGF-b and IL-10 pathways crosstalk with the participation of
TGF-b in the differentiation of IL-10-producing T cells. Additional
insights into themolecular and cellular mechanisms bywhich the
dual cytokine pathways regulate peripheral T cell responses will
aid the targeting of TGF-b1 and IL-10 for the therapy of various
inflammatory disorders.
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